News

January 13, 2020January 13, 2020

Veyonda Plus Low-dose Radiotherapy May Halt Disease Progression in Late-Stage PC, Study Suggests

News

Noxopharm’s Veyonda (idronoxil), in combination with low-dose radiation therapy, safely halted disease progression and eased pain in men with late-stage metastatic castration-resistant prostate cancer (mCRPC), according to results from a Phase 1b clinical ... Read more

January 8, 2020

US Congress Increases Funding for Prostate Cancer Research for FY 2020

News

To foster more research projects in prostate cancer, the U.S. Congress has increased funding for the Department of Defense’s Prostate Cancer Research Program (PCRP) by $10 million, to $110 million, for ... Read more

January 6, 2020January 30, 2020

EMA Committee Favors Extending Use of Erleada for Metastatic Castration-sensitive Prostate Cancer

News

The Committee for Medicinal Products for Human Use recommends extending the use of Janssen’s Erleada (apalutamide), in combination with androgen deprivation therapy (ADT), to treat men with metastatic hormone-sensitive prostate cancer ... Read more

December 30, 2019January 9, 2020

PyL Imaging Agent Accurately Detects Recurrent Prostate Cancer Lesions, Trial Shows

News

Progenics Pharmaceuticals’ PyL, a new imaging agent for positron emission tomography (PET) scans, can accurately detect the location of recurrent prostate cancer lesions, according to data from a Phase 3 clinical trial. “The ... Read more

December 19, 2019December 19, 2019

Lynparza Particularly Effective in Prostate Cancer Patients Carrying BRCA Mutations, Phase 2 Study Shows

News

Lynparza (olaparib), a breast and ovarian cancer treatment, is also showing promising results in men with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in DNA repair genes, particularly the BRCA1 ... Read more

December 18, 2019December 18, 2019

FDA Expands Xtandi Approval to Include Metastatic Castration-sensitive Prostate Cancers

News

The U.S. Food and Drug Administration (FDA) has agreed to expand Xtandi‘s (enzalutamide) approval to include men whose metastatic prostate cancer still responds to hormone therapy, Astellas Pharma and Pfizer, the treatment’s developers, announced. ... Read more

December 16, 2019December 16, 2019

Prostate Cancer Campaigns Boost Enrollment in Study to Validate ClarityDX Diagnostic Test in Canada

News

Campaigns by Movember and the Alberta Cancer Foundation have helped to raise the number of men enrolled to more than 200 in the validation study of ClarityDX Prostate, a new ... Read more

December 12, 2019

Blank Family Foundation Donates $1M to Mount Sinai for Prostate Cancer Research

News

The Arthur M. Blank Family Foundation has given $1 million to the Icahn School of Medicine at Mount Sinai‘s urology department to support research into prostate cancer. Together with an earlier foundation gift ... Read more

December 11, 2019

Lower Prostate Cancer Risk in Diabetics Likely Due to Fewer Biopsies, Not Medications, Study Says

News

Common treatments for diabetes don’t appear to mask or reduce levels of a prostate cancer marker in the blood. Rather, the lower rates of prostate cancer detected in men with ... Read more

December 9, 2019

Onvansertib Helps Overcome Resistance to Zytiga in mCRPC Patients, Interim Phase 2 Data Show

News

Trovagene’s investigational oral therapy onvansertib may help overcome resistance to Zytiga (abiraterone acetate) in men with metastatic castration-resistant prostate cancer (mCRPC), updated Phase 2 data continue to suggest. The trial (NCT03414034) ... Read more